Matt

2.4K posts

Matt

Matt

@IndustryRPh

Biotech market access; ex-Lilly; market student; My personal opinions

Katılım Ekim 2016
1.2K Takip Edilen928 Takipçiler
Matt
Matt@IndustryRPh·
@given2tweet negative development on AKRO CVR, estimated trial extension. can dm you the note if you didnt get it
English
0
0
2
30
Matt
Matt@IndustryRPh·
@_skobee_ Hah that's a good clip
English
0
0
1
6
𝚜𝚔𝚘𝚋𝚎𝚎 ☻
I hate that I kind of love this show. anyway — good morning. it’s the jews
English
34
99
1.2K
13.7K
Matt
Matt@IndustryRPh·
@BartHanson Nice trick There is no min eff stack. Negative EV regardless
English
3
0
3
2.2K
Bart Hanson
Bart Hanson@BartHanson·
I asked this at my Harvard lecture and none of the students got it: In a $100 pot we have 65dd on btn after calling a UTG preflop raise. Board Ks7c3h. UTG pots $100. We know he has AA and will stack off. What is the min eff stack on the flop before the bet to make a call profit
English
79
2
146
157.4K
Matt
Matt@IndustryRPh·
@given2tweet Crude contracts for this fall are going down
English
1
0
0
93
Matt
Matt@IndustryRPh·
@TMTLongShort But yeah you are cycling low dose reta. Shouldn't need to worry that much but hey we are all just guessing
English
0
0
1
20
Matt
Matt@IndustryRPh·
@TMTLongShort An academic would tell you "we need more data" to answer My short answer is reta seems to increase heart rate a bit more than tirzepatide. Framingham showed higher HR has higher risk of mortality The moonshot guys will agree we want to lower HR for longevity
English
2
0
1
187
Just Another Pod Guy
Just Another Pod Guy@TMTLongShort·
I legitimately changed my risk tolerance for things based on my assumption that there is a high probability cancer will be cured in the next two decades due to AI. Will be interesting to see how this plays out on a societal level as more people turn maxi.
Under the Sunshine@UndertheSunshi4

@TMTLongShort Will be an unpleasant sight to witness an upcoming gut cancer spike among Americans in 15-20 years...

English
13
5
197
37.8K
Matt
Matt@IndustryRPh·
Aakash Gupta@aakashgupta

Walmart just crossed $1 trillion in market cap and nobody can explain the P/E. The answer is sitting in one line of their earnings call. CFO John Rainey said advertising and membership now generate 50% of Walmart’s incremental profit. Read that again. Half the profit growth is coming from a business that didn’t exist five years ago. Walmart Connect did $4.4 billion in ad revenue in fiscal 2025 and grew 31% in Q1 FY26 before you even count VIZIO. Include VIZIO, and global ad revenue jumped 50% in a single quarter. The ad business alone is approaching the size of a mid-cap SaaS company, except it runs on 4,700 physical stores worth of first-party purchase data. The market isn’t pricing Walmart as a retailer anymore. A grocery chain trades at 12-15x earnings. A retail media platform with closed-loop attribution, connected TV inventory, and 270 million weekly shoppers trades like a tech company. Because it is one. Meta trades at 22x forward earnings with ad revenue growing ~20%. Walmart trades at 44x forward earnings with ad revenue growing 50%. The bull case is that Walmart’s ad business is earlier on its S-curve than Meta’s, and the total addressable market keeps expanding as every CPG brand shifts spend from linear TV to retail media. The 20,000% all-time chart looks parabolic because the business model flipped. Walmart spent 60 years optimizing for pennies on grocery margins. Now it monetizes the traffic those groceries generate. Every dollar of ad revenue drops at software-like margins into a business doing $680 billion in sales. The bear case is real: 46x trailing P/E on a company growing top-line revenue at 5% is a bet that advertising and marketplace fees compound for another decade without compression. If ad growth slows to 15-20%, the multiple contracts fast. But right now, the market is pricing the transition, and the transition is actually working.

QME
0
0
0
220
Quinn Thompson
Quinn Thompson@qthomp·
Walmart is now the 10th largest US public company by market cap at just over $1T, not far behind Berkshire in the 9th spot. Who has the best explanation for why $WMT and $COST trade at the valuation multiples they do?
Quinn Thompson tweet mediaQuinn Thompson tweet media
English
23
2
61
16.5K
Matt
Matt@IndustryRPh·
@mikealfred Seem to me it also is due to their ability to raise via secured notes as announced this AM
English
2
0
1
786
Matt
Matt@IndustryRPh·
@T_OConnell $6 until we get Tim back briefly🙏
English
0
0
0
54
Matt
Matt@IndustryRPh·
@given2tweet Costco stopping the gift card trick is devastating
English
1
0
0
68
Matt
Matt@IndustryRPh·
@seedy19tron I am starting a company and we will pre announce that we will be pre announcing our preannouncement
GIF
English
1
0
9
1.3K
Seedy19
Seedy19@seedy19tron·
$CRVS with a pre pre announcement + pre announcement + 5 am PT CC
GIF
English
9
1
66
14.2K
Matt
Matt@IndustryRPh·
@FransBakker9812 I agree Frans, biotech isn't for most retail. Biotechs are mostly for shorting unless you know what to look for
Matt@IndustryRPh

@mikealfred Probably. Biotech already mid way in the highest quality companies. We discussed most of my largest positions below last chat. Another good launch with a legendary CEO is NUVB. GLUE is about to get more traction

English
0
0
2
459
Frans Bakker
Frans Bakker@FransBakker9812·
I am the last person to take investing, or financial advice from, so don't misconstrue this as such. But I will tell you this much: Biotech stocks have no floor. I like my 4 or 5 9's as uptime, but not as drawdowns. $IREN has a solid asset base with a guaranteed floor. Biotech stocks to me represent the miscreant baby of a gamble addict and a shitcoiner. GL and HF.
English
17
1
223
31.1K